{"entity":{"id":"nct06850103","kind":"trial","name":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","aka":[],"tldr":"A phase 2 trial of serplulimab in colorectal cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.","summary":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases is a phase 2, interventional study registered as NCT06850103 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 51 participants, started 2025-04-22 and due to reach its primary completion in 2027-12-31. Interventions recorded: short-course radiotherapy; CAPEOX/XELOX; Serplulimab; surgery. Conditions listed: Colorectal Carcinoma; Oligometastases; pMMR; MSS; iTNT. Primary outcome: 3-year PFS. Colorectal eligibility wording from the registry: \"Histologically confirmed primary rectal adenocarcinoma, with MRI showing tumor location within 10cm from the anal verge\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06850103","url":"https://clinicaltrials.gov/study/NCT06850103"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["serplulimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06850103","phase":"2","setting":"A Phase II Exploratory Multicenter Randomized Controlled Clinical Trial to Evaluate the Effectiveness of Neoadjuvant Short-Course Radiotherapy (SCRT) Followed by CAPEOX Chemotherapy and Serplulimab in Microsatellite Stable (MSS) or Proficient Mismatch Repair (pMMR) Rectal Cancer With Synchronous Oligometastases","sponsor":"First Affiliated Hospital of Zhejiang University","enrolled":51,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06850103/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}